MHRA Drug Safety Update – March 2018

MHRA Drug Safety Update – March 2018

March 12, 2018

Date Issued: 8th March 2018

A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 11, Issue 8, March 2018) has been published and includes articles on:

  • daclizumab (Zinbryta▼): suspension and recall for safety reasons; review patients as soon as possible and start alternative therapy;
  • Esmya (ulipristal acetate) for uterine fibroids: do not initiate or re-start treatment; monitor liver function in current and recent users; and
  • head lice eradication products: risk of serious burns if treated hair is exposed to open flames or other sources of ignition, for example, cigarettes.

To see the latest MHRA Drug Safety Update in full, visit the website.

Posted in:

More Latest News >

Menadiol 10mg tablets supply issue

PSNC has become aware that Alliance Pharmaceuticals Ltd has transferred the production of its licensed Menadiol Diphosphate Tablets 10mg to...

Health & Care Review

Plans to cut excess calorie consumption unveiled Public Health England (PHE) has announced new measures to help reduce people’s excessive...